orforglipron oral GLP-1
Selected indexed studies
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. (N Engl J Med, 2023) [PMID:37351564]
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. (N Engl J Med, 2025) [PMID:40960239]
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. (N Engl J Med, 2025) [PMID:40544435]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. (2023) pubmed
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. (2025) pubmed
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. (2023) pubmed
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. (2025) pubmed
- The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. (2024) pubmed
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. (2023) pubmed
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. (2023) pubmed
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. (2023) pubmed
- Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. (2026) pubmed
- Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes. (2025) pubmed